Navigation Links
Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
Date:9/1/2008

NATICK, Mass. and MUNICH, Germany, Sept. 1 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced one-year data from its landmark SYNTAX trial comparing percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System to contemporary coronary artery bypass graft (CABG) surgery. The overall results demonstrated no statistically significant differences between PCI and CABG in rates of death or myocardial infarction (MI). The Company made the announcement at the annual European Society of Cardiology meeting in Munich, Germany.

The SYNTAX trial is the first randomized, controlled clinical trial to compare PCI using drug-eluting stents (DES) to CABG in patients with left main disease and three-vessel disease. These patient groups are typically treated with CABG and represent a population with far more complex anatomy and advanced disease than those studied in prior DES clinical trials. The goal of the trial is to expand the body of knowledge of PCI use and help inform physicians on appropriate treatment options for the sickest patients.

"For PCI patients to do so well with such complex anatomy and advanced disease is extraordinary," said Keith Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "These patients, the majority of whom are normally treated with surgery, are the most challenging group ever studied in a DES clinical trial."

The SYNTAX trial also demonstrated a significant decrease in the rate of stroke for patients treated with PCI as compared to CABG.

"The significant difference in the stroke rate between the PCI and the CABG groups is an important finding," said Dr. Dawkins. "Physicians and their patients will
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease
2. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
3. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
4. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
5. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
6. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
7. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
10. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
11. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 Pfanstiehl has ... (USP/NF, EP), manufactured in the USA ... has long been recognized for playing a key ... growing body of evidence that media supplementation with ... of protein glycosylation," according to Dr. Christopher ...
(Date:10/1/2014)... Washington, USA (PRWEB) September 30, 2014 ... yet efficient arrangements that have evolved in nature over ... biomimetic and bioinspired materials for applications in biophotonics ... Biomedical Optics . The journal is published by SPIE, ... SPIE Digital Library. Several of the peer-reviewed articles are ...
(Date:10/1/2014)... Sept. 30, 2014 This report ... in US$ Million by the following Product ... Enzymes. Specific end-use segments also analyzed are ... The report provides separate comprehensive analytics ... Middle East, and Latin America. Annual estimates ...
(Date:9/30/2014)... of one of nature,s most efficient light-harvesting structures, ... by Alejandro Briseno of the University of Massachusetts ... long-sought polymer architecture to boost power-conversion efficiency of ... , Briseno, with colleagues and graduate students ... and Dresden University of Technology, Germany, report in ...
Breaking Biology Technology:Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3
... of its Board of Directors, held today, Wyeth (NYSE: ... of the Company.A dividend of thirty cents ($.30) per share on ... 1, 2009 to stockholders of record at the close of business ... cents ($.50) per share on the outstanding shares of Preferred Stock ...
... William White, Continental Airlines CEO Larry Kellner, and the ... CAMBRIDGE, Mass., April 23 TechConnect World today announced ... the TechConnect World trio of conferences -- ... TechConnect Summit events, at the George R. Brown Convention ...
... SQNM ), today announced that it will report first ... 2009. The company will conduct a conference call and an ... on the same day., Conference Call Information:, ... callers: 1 (706) 679-9912, , , Webcast information: ...
Cached Biology Technology:TechConnect World Conference Showcases Houston Leaders May 3-7, at the George R. Brown Convention Center 2TechConnect World Conference Showcases Houston Leaders May 3-7, at the George R. Brown Convention Center 3SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30 2
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
(Date:9/29/2014)... study confirms that the exposure to tar tended to ... regular cigarettes. Similarly, exposure to nicotine tended to ... type of cigarette in several countries around the world. ... toxic chemicals in the smoke of these cigarettes are ... levels of chemicals in the smoke are not necessarily ...
(Date:9/29/2014)... Parents with children at home should use ventilation when ... University are recommending, after a new study showed an ... symptoms and chronic bronchitis. , "In homes where a ... asthma and wheezing is higher than in homes where ... Smit, an associate professor in the College of Public ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Slim cigarette smokers not exposed to more harmful chemicals 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3
... CLEVELAND, Ohio - Cleveland Botanical Garden and Kent State ... pioneering scientific center for research in the field - ... research greenhouses on the Gardens campus. By ... the partnership could, in effect, control sunlight, extending the ...
... Pixelplus Co.,Ltd. (Nasdaq: PXPL ), ... designs,develops, and markets CMOS image sensors for ... unveiled the "PM1002", the Company,s,new ,System-On-A-Chip, ("SoC") ... PM1002 integrates a 32-bit RISC microprocessor and ...
... intricate transfer of information from a segment of DNA ... stationed in special "transcription factories" within a cell nucleus, ... II (Pol II) and other key molecules can assemble ... the gene,s position., The findings, published in the Dec. ...
Cached Biology News:Research project aims to control sunlight, extend growing season and conserve energy 2Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition 2Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition 3Research sheds light on the mechanics of gene transcription 2
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
ASCIZ...
...
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Biology Products: